Literature DB >> 29208604

JCAR015 in ALL: A Root-Cause Investigation.

.   

Abstract

After conducting an internal probe of the five deaths that halted JCAR015's development for acute lymphoblastic leukemia, Juno Therapeutics has concluded that multiple factors were at play. A surge in inflammatory cytokine levels from rapid, early T-cell proliferation may have provoked the blood-brain barrier disruption seen in these patients, inducing fatal cerebral edema. ©2018 American Association for Cancer Research.

Entities:  

Year:  2017        PMID: 29208604     DOI: 10.1158/2159-8290.CD-NB2017-169

Source DB:  PubMed          Journal:  Cancer Discov        ISSN: 2159-8274            Impact factor:   39.397


  16 in total

1.  Intrathecal chemotherapy for management of steroid-refractory CAR T-cell-associated neurotoxicity syndrome.

Authors:  Nirav N Shah; Bryon D Johnson; Timothy S Fenske; Renju V Raj; Parameswaran Hari
Journal:  Blood Adv       Date:  2020-05-26

Review 2.  Clinical experience of CAR T cells for B cell acute lymphoblastic leukemia.

Authors:  Vanessa A Fabrizio; Kevin J Curran
Journal:  Best Pract Res Clin Haematol       Date:  2021-08-27       Impact factor: 3.670

Review 3.  Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.

Authors:  Cassie K Chou; Cameron J Turtle
Journal:  Expert Opin Biol Ther       Date:  2020-02-24       Impact factor: 4.388

4.  Multifocal Necrotizing Leukoencephalopathy With Preferential Microglia Toxicity in a Patient Treated With Chimeric Antigen Receptor T-Cells and Review of the Literature.

Authors:  Daniel F Marker; Julia K Kofler; Joseph A Mettenburg; Mounzer E Agha; Clayton A Wiley
Journal:  J Neuropathol Exp Neurol       Date:  2020-10-01       Impact factor: 3.685

Review 5.  State of the art in CAR T cell therapy for CD19+ B cell malignancies.

Authors:  Matthew J Frigault; Marcela V Maus
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

6.  Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma.

Authors:  Matthew J Frigault; Jorg Dietrich; Maria Martinez-Lage; Mark Leick; Bryan D Choi; Zachariah DeFilipp; Yi-Bin Chen; Jeremy Abramson; Jennifer Crombie; Philippe Armand; Lakshmi Nayak; Chris Panzini; Lauren S Riley; Kathleen Gallagher; Marcela V Maus
Journal:  Blood       Date:  2019-07-18       Impact factor: 25.476

Review 7.  Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?

Authors:  Paula Salmikangas; Niamh Kinsella; Paul Chamberlain
Journal:  Pharm Res       Date:  2018-05-31       Impact factor: 4.200

Review 8.  Cellular immunotherapies for cancer.

Authors:  Conall Hayes
Journal:  Ir J Med Sci       Date:  2020-07-01       Impact factor: 1.568

Review 9.  Chimeric Antigen Receptor T-Cell Therapy Clinical Results in Pediatric and Young Adult B-ALL.

Authors:  Amanda M DiNofia; Shannon L Maude
Journal:  Hemasphere       Date:  2019-08-07

Review 10.  Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer.

Authors:  Amy J Petty; Benjamin Heyman; Yiping Yang
Journal:  Cancers (Basel)       Date:  2020-03-31       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.